Xerostomia Market is Expected to Witness Significant Growth by 2036 Due to Rising Disease Burden and Emerging Novel Therapies | DelveInsight

The market dynamics for Xerostomia are anticipated to witness notable growth driven by the increasing prevalence of xerostomia associated with aging populations, rising polypharmacy use, increasing cases of Sjogren's syndrome, growing head and neck cancer survivorship, and improved awareness regarding oral health management. Additionally, the development of emerging therapies such as LBS-020, AAV-hAQP1, and others will further support the expansion of the xerostomia treatment market.
DelveInsight, a leading market research firm, announces the release of its latest report, "DelveInsight's Xerostomia Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Xerostomia, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Xerostomia Market

*
The market size for Xerostomia in the leading markets is expected to increase significantly during the forecast period 2022-2036.

*
The United States accounted for the highest Xerostomia market size among the 7MM in 2025 compared to EU4 countries, the United Kingdom, and Japan.

*
According to Huang et al. (2025), a systematic review and meta-analysis involving 2,486 patients with type 2 diabetes across 16 countries reported an overall xerostomia prevalence of 42.5%, highlighting diabetes as a major contributor to xerostomia burden globally.

*
According to Rughwani et al. (2025), a Swedish study involving 1.39 million adults reported a diagnosed xerostomia prevalence of 0.23%, with nearly 73.1% of cases occurring in women and 41.5% in individuals aged above 71 years.

*
According to the European Association of Oral Medicine (2022), xerostomia occurs in approximately 17-39% of individuals aged 65 years or older and is more frequently observed in women than men.

*
Leading Xerostomia companies such as Lubris BioPharma, MeiraGTx, and others are developing innovative therapies aimed at improving salivary gland function and long-term disease management.

*
Promising Xerostomia pipeline therapies include LBS-020 and AAV-hAQP1, among others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/xerostomia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Xerostomia Market

Increasing Disease Burden and Aging Population:The growing prevalence of xerostomia among elderly populations, patients with chronic diseases, and individuals undergoing head and neck radiation therapy is significantly contributing to market growth.

Rising Demand for Effective Symptomatic Therapies:Current therapies such as pilocarpine and cevimeline continue to remain widely used for improving salivary secretion and reducing oral discomfort associated with xerostomia.

Growing Focus on Regenerative and Gene-based Therapies:Pharmaceutical companies are increasingly focusing on regenerative salivary gland therapies, gene therapies, stem cell approaches, and radioprotective agents that may offer disease-modifying benefits beyond temporary symptom relief.

Xerostomia Competitive Landscape

*
Several Xerostomia therapies in development include LBS-020 (Lubris BioPharma) and AAV-hAQP1 (MeiraGTx).

*
These therapies target diverse mechanisms such as recombinant lubricin-based oral lubrication and aquaporin-1 gene therapy designed to restore salivary gland function and improve saliva production in radiation-induced xerostomia patients.

Discover more about therapies set to grab major Xerostomia market share @ Xerostomia Treatment Landscape [https://www.delveinsight.com/sample-request/xerostomia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Xerostomia Market

*
In April 2026, MeiraGTx announced presentation of 3-year data from the Phase I AQUAx clinical study evaluating AAV-hAQP1 for Grade 2/3 radiation-induced xerostomia.

*
AAV-hAQP1 is currently being evaluated in Phase III clinical trials for radiation-induced xerostomia.

*
Lubris BioPharma continues to advance LBS-020 as a novel recombinant lubricin-based therapy designed to improve oral lubrication and provide longer-lasting symptomatic relief compared to traditional saliva substitutes.

*
Researchers in the United States are also developing reusable hydrogel reservoir technologies capable of gradually releasing artificial saliva in the oral cavity, potentially providing sustained symptom relief for xerostomia patients.

What is Xerostomia?

Xerostomia is defined as the subjective sensation or complaint of oral dryness. It may result from reduced salivary secretion due to salivary gland dysfunction or may occur despite normal salivary gland activity.

The condition is commonly associated with medications, autoimmune diseases, endocrine disorders, head and neck radiation therapy, chemotherapy, and lifestyle factors. Patients often experience difficulty swallowing, speaking, chewing, altered taste, oral infections, and dental complications that significantly affect quality of life.

Currently approved systemic therapies for xerostomia include pilocarpine (SALAGEN) and cevimeline (EVOXAC), while topical therapies and saliva substitutes remain important supportive treatment options.

Xerostomia Epidemiology Segmentation

The Xerostomia epidemiology section provides insights into the historical and current Xerostomia patient pool and forecasted trends for the leading markets. The Xerostomia market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

*
Total Diagnosed Prevalent Cases of Xerostomia

*
Treatment Eligible Cases of Xerostomia

*
Age-specific Diagnosed Prevalent Cases of Xerostomia

*
Gender-specific Diagnosed Prevalent Cases of Xerostomia

Scope of the Xerostomia Market Report

*
Therapeutic Assessment: Xerostomia current marketed and emerging therapies

*
Xerostomia Market Dynamics: Key Market Forecast Assumptions and Market Outlook

*
Key Companies: Lubris BioPharma, MeiraGTx, and others

*
Key Therapies: LBS-020, AAV-hAQP1, Pilocarpine (SALAGEN), Cevimeline (EVOXAC), and others

*
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

*
Unmet Needs, KOL's views, Analyst's views, Xerostomia Market Access and Reimbursement

To know more about Xerostomia companies working in the treatment market, visit @ Xerostomia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/xerostomia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Xerostomia Market Report Introduction

*
Executive Summary for Xerostomia

*
SWOT Analysis of Xerostomia

*
Xerostomia Patient Share (%) Overview at a Glance

*
Xerostomia Market Overview at a Glance

*
Xerostomia Background and Overview

*
Xerostomia Epidemiology and Patient Population

*
Country-Specific Patient Population of Xerostomia

*
Xerostomia Current Treatment and Medical Practices

*
Xerostomia Unmet Needs

*
Xerostomia Emerging Therapies

*
Xerostomia Market Outlook

*
Country-Wise Xerostomia Market Analysis (2022-2036)

*
Xerostomia Market Access and Reimbursement of Therapies

*
Xerostomia Market Drivers

*
Xerostomia Market Barriers

*
Xerostomia Appendix

*
Xerostomia Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=xerostomia-market-is-expected-to-witness-significant-growth-by-2036-due-to-rising-disease-burden-and-emerging-novel-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/consulting/due-diligence-services
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.